SCHEMBL4057796

SCHEMBL4057796

CC(C)(C)OC(=O)N1CC=CC1(C)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.43
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
RORC P51449 6/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TSHR P16473 2/20 0.40
ALOX15 P16050 1/20 0.40
ATM Q13315 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
BCHE P06276 1/20 0.38
TACR1 P25103 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4062459 0.80 MAPK1 (0.51) MAPK1MEN1KMT2AALDH1A1CYP3A4
SCHEMBL27738898 0.78 NR1H2 (0.57) NR1H2NR1H3RORCTSHRALOX15
SCHEMBL27738889 0.78 NR1H2 (0.57) NR1H2NR1H3RORCTSHRALOX15
SCHEMBL2495889 0.76 CYP3A4 (0.60) MAPK1NR1H2NR1H3MEN1KMT2A
SCHEMBL28704785 0.76 CYP3A4 (0.60) MAPK1NR1H2NR1H3MEN1KMT2A
SCHEMBL4068506 0.74 NR1H2 (0.46) NR1H2NR1H3RORCTSHRALOX15
SCHEMBL4976100 0.74 NR1H2 (0.46) NR1H2NR1H3RORCTSHRALOX15
SCHEMBL18642718 0.73 NR1H2 (0.53) NR1H2NR1H3RORCTSHRALOX15
SCHEMBL16004573 0.73 NR1H2 (0.53) NR1H2NR1H3RORCTSHRALOX15
SCHEMBL28815574 0.73 NR1H2 (0.53) NR1H2NR1H3RORCTSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515724-B1 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2009-10-21 EP disclosed
US-7348440-B2 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator MERCK & CO., INC. (US) 2008-03-25 US disclosed
US-20060105997-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060105997-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIF18B MAPK1 1272/4885NR1H2 2816/4885NR1H3 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.